Landiolol, an Ultra-Short-Acting β<sub>1</sub>-Blocker, More Effectively Terminates Atrial Fibrillation Than Diltiazem After Open Heart Surgery
Abstract
Background: Recent studies have suggested that esmolol is the first choice for rate control in patients with postoperative atrial fibrillation (AF) after coronary artery bypass surgery, but side-effects of esmolol such as hypotension are problematic. To overcome this problem, landiolol, an ultra-short-acting β1-blocker with a less negative inotropic effect than esmolol, has been developed. The aim of the present study was to investigate whether...
Paper Details
Title
Landiolol, an Ultra-Short-Acting β<sub>1</sub>-Blocker, More Effectively Terminates Atrial Fibrillation Than Diltiazem After Open Heart Surgery
Published Date
Jan 1, 2012
Journal
Volume
76
Issue
5
Pages
1097 - 1101
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History